![](https://investorshub.advfn.com/uicon/48355.png?cb=1551739062)
Friday, January 09, 2015 5:58:35 PM
http://ih.advfn.com/p.php?pid=nmona&article=65043919
Also:
Gilead Sciences, Inc. (NASDAQ:GILD) Looks Forward To Acquiring Arrowhead Research Corp (NASDAQ:ARWR) 0
BY THOMAS COPELAND ON JANUARY 1, 2015 BIOPHARMA
News has it that Gilead Sciences, Inc. (NASDAQ:GILD) is looking forward to sealing an acquisition deal with Arrowhead Research Corp (NASDQ:ARWR). The company bought a small cap of the latter’s stock, and now it wants to acquire the whole company. According to the news, the healthcare giant wants to acquire Arrowhead for its hepatitis B drugs. The pipeline of Arrowhead is very strong, as it contains ARC-520 drug.
Arrowhead Research Corp (NASDAQ:ARWR) is based in California. The company has a number of important drugs in its pipeline; some of them being the experimental ones. The ARC-520 drug of Arrowhead is being tested for the cure of hepatitis B. Another significant drug that Arrowhead is testing is an anti-obesity one.
Gilead Sciences, Inc. (NASDAQ:GILD) recently bought some stocks in Arrowhead, causing the share price of Arrowhead to go up by 14.5 percent. The average trading volume for 30 day period was recorded to be at 2.23 million; however, the stocks volume reached 11.7 million as soon as Gilead bought the shares.
The stocks of Arrowhead plummeted in the last few months, due to a rough period that the company was going through. The company released a research report on the phase 2 trial study of one of its hepatitis drugs: the results of the study were not very favorable, causing the investors to trade their shares. The results were even weaker than what the company and the analysts were expecting. Some of the investors sought help from law firms and filed suits against the company, alleging that Arrowhead did not reveal the full information about the drug, and thus tricked the investors into investing their money on the experimental drug.
The chief executive of Arrowhead, Christopher Anzalone, on the other hand, is very confident about the company, especially the technology that it is developing in its test units in Madison. According to Christopher, the company has investment in research and development, which is not a bad choice. He further stated that the investments will pay off very soon.
That said, Arrowhead can only afford to lose a few competitions, for the situation in healthcare industry is quite tense at the moment. It is important to mention here that ARC-520 is an RNA interference drug. Gilead Sciences, Inc. (NASDAQ:GILD) has 3 products in its pipeline; however, none of them is an RNA interference drug. The only other company that is developing and RNA interference drug for hepatitis B is Alnylam Pharmaceuticals (NASDAQ:ALNY)
Gilead Sciences, Inc. (NASDAQ:GILD) currently has $6.2 billion cash lying around, so it can surely afford Arrowhead. The acquisition will not only improve its pipeline for hepatitis B drugs but it will also make the company’s position a dominant one in the market. Since the market for hepatitis drugs is quite big- around 5 percent of the total population suffers from it- Gilead Sciences, Inc. (NASDAQ:GILD) will be making a positive decision from the point of view of sales, profits and revenues.
DUKE BASKETBALL and NOTRE DAME FOOTBALL
Recent IONS News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 01:29:02 PM
- Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema • PR Newswire (US) • 06/18/2024 11:00:00 AM
- Ionis to present at TD Cowen Genetic Medicines & RNA Summit • PR Newswire (US) • 06/17/2024 08:09:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 02:59:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:33:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 11:15:31 AM
- Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema • PR Newswire (US) • 05/31/2024 11:00:00 AM
- Ionis to hold donidalorsen Phase 3 data webcast • PR Newswire (US) • 05/28/2024 11:00:00 AM
- New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) • PR Newswire (US) • 05/23/2024 11:00:00 AM
- Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • GlobeNewswire Inc. • 05/16/2024 11:30:14 AM
- Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • PR Newswire (US) • 05/16/2024 11:30:00 AM
- Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome • PR Newswire (US) • 05/16/2024 11:00:00 AM
- Ionis to host 2024 virtual Annual Meeting of Stockholders • PR Newswire (US) • 05/15/2024 11:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 09:25:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:55:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 07:55:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 03:15:41 PM
- Ionis reports first quarter 2024 financial results • PR Newswire (US) • 05/07/2024 11:00:00 AM
- Ionis Publishes 2023 Corporate Responsibility Report • PR Newswire (US) • 04/25/2024 11:00:00 AM
- Ionis to hold first quarter 2024 financial results webcast • PR Newswire (US) • 04/23/2024 11:05:00 AM
- Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome • PR Newswire (US) • 04/07/2024 01:48:00 PM
- Ionis to present at upcoming investor conferences • PR Newswire (US) • 04/01/2024 11:05:00 AM
- Ionis to hold olezarsen Phase 3 data webcast • PR Newswire (US) • 03/28/2024 11:05:00 AM
- Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting • PR Newswire (US) • 03/25/2024 12:18:00 PM
- Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH • PR Newswire (US) • 03/13/2024 11:00:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM